February 23, 2012 - ZOLL Sponsors Latin America's First Symposium on Therapeutic Temperature Mangement
INVESTOR CONTACT: |
A. Ernest Whiton |
MEDIA CONTACT: |
Diane Egan |
ZOLL SPONSORS LATIN AMERICA’S FIRST SYMPOSIUM ON THERAPEUTIC TEMPERATURE MANAGEMENT
Keynote Speakers Discuss Indications and Success of the Life-Saving Technology
February 23, 2012─CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it recently provided an education grant to sponsor the “Seminario Internacional de Hipotermia: Innovadora Modalidad de Neuroproteccion,” Latin America’s first symposium on therapeutic temperature management in Panama City, Panama. The symposium highlighted the successful use of temperature management for cooling and warming a patient’s body temperature for a range of acute neurological diseases.
The conference attracted close to 100 critical care and intensive care physicians, cardiologists, neurologists, neurosurgeons, and nurses from across the region, who came to learn about advances and case studies in this emerging field of life-saving technology.
According to Guadalupe Castillo Abrego, MD, Medical Director Neurocritical Care Unit Caja de Seguro Social Hospital and Neuro and Critical Care Staff Physician at the Johns Hopkins-affiliated Punta Pacifica Hospital, the conference presentations spanned a range of topics relevant to therapeutic hypothermia including the benefits of therapeutic hypothermia post-cardiac arrest*; physiological changes, mechanism of actions and considerations in therapeutic hypothermia patients; the importance of temperature management in the treatment of acute brain and or spinal cord injury; therapeutic hypothermia protection after cerebral ischemia and trauma; the induction, maintenance and heating during therapeutic hypothermia; the development and implementation of therapeutic hypothermia programs at hospitals; and chills and fever control in the setting of acute brain injury.
“Conference attendees were addressed by some of the foremost practitioners in this quickly emerging field of life-saving technology who were able to impart first-hand knowledge on the relevance of therapeutic hypothermia,“ said Dr. Castillo Abrego. “Attendees learned the benefits of therapeutic hypothermia for a widening range of indications, including post-cardiac arrest, head trauma, acute spinal injury, stroke, and seizures.”
“Much of the discussion was on neurological outcome for patients treated with therapeutic hypothermia, and the benefits of precise temperature control,” said James Palazzolo, President of ZOLL. “This innovative approach to neuroprotection is at the forefront of advancing critical care and improving outcomes from a range of life-altering indications.”
The panel of leading international experts in temperature management who gave keynote presentations at the conference included:
- Kees Polderman, MD, PhD, University of Pittsburgh, formerly University of Utrecht, (Netherlands); Neurocritical Care Society Board Director
- W. Dalton Dietrich, PhD, University of Miami, Editor in Chief of Neurotrauma Journal and Therapeutic Hypothermia and Temperature Management Journal
- Gene Sung, MD, Head of the Department of Stroke and Neurointensive Care, University of California at Los Angeles (UCLA); Founding member and president of the Neurocritical Care Society International
- Kiwon Lee, MD, Neurocritical Care and Stroke Neurologist, Professor of Neurocritical Care Unit, Columbia Presyterian Hospital, New York
Upcoming therapeutic hypothermia and temperature management conferences for which ZOLL is providing an educational grant in 2012 include the second annual U.S. “Chilling at the Beach,” in Miami in March and “Chilling at the Beach,” in Slovenia Europe in June.
About ZOLL IVTM
ZOLL IVTM provides cooling and warming from a catheter inserted into a patient’s vein. This provides better control of the core body temperature by directly cooling or warming the patient’s blood as it flows through the body. This catheter is connected to the Thermogard XP® console, which when used to induce hypothermia, circulates ice-cold saline solution inside a balloon catheter. After a period of therapeutic hypothermia, typically 12-24 hours, the system slowly and accurately rewarms the patient back to normal body temperature. Since the saline flows only within the catheter, no fluid is infused into the patient. The ZOLL IVTM system is efficient, precise and easy to use, and frees up clinical staff to attend to other patient needs.
ZOLL IVTM offers a variety of catheters with placement options to handle specific patient challenges. Options for catheter placement include femoral, subclavian, and internal jugular.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on November 23, 2011, as updated by the Company’s subsequent SEC filings, including Quarterly Reports on Form 10-Q. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2012 ZOLL Medical Corporation. All rights reserved. IVTM and ZOLL are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All trademarks are the property of their respective owners.
*Not FDA approved for use in the U.S.